This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (13) Citing Articles via Google Scholar Google Scholar Articles by Buntin-Mushock, C. Articles by Palmer, P. P. Search for Related Content PubMed PubMed Citation Articles by Buntin-Mushock, C. Articles by Palmer, P. P. Related Collections Pain Pharmacology

---

PAIN MEDICINE

Age-Dependent Opioid Escalation in Chronic Pain Patients

Chante Buntin-Mushock, MD^*, Lisa Phillip, MD^*, Kumi Moriyama, MD^*, and Pamela Pierce Palmer, MD, PhD^*

Departments of *Anesthesia and Perioperative Care and Neurology, University of California, San Francisco

Address correspondence and reprint requests to Pamela Pierce Palmer, MD, PhD, University of California, San Francisco, Department of Anesthesia and Perioperative Care, 513 Parnassus Ave., Box 0464, Room S-455, San Francisco, CA 94143. Address e-mail to palmerp{at}anesthesia.ucsf.edu.

Rapid opioid dose escalation, possibly caused by tolerance, has been observed in some patients on daily opioid therapy, although clinically identifiable characteristics of these patients are unknown. In this retrospective chart review of 206 patients, we examined whether the age of the patient was related to opioid escalation. Initial starting doses of long-acting opioids were similar in younger patients (50 yr; 49 ± 3 mg/d oral morphine-equivalent dose) versus older patients (60 yr; 42 ± 3 mg/d). Younger patients reached a maximum dose of 452 ± 63 mg/d over 15.0 ± 1.3 mo, whereas older patients achieved a maximum dose of 211 ± 23 mg/d over 14.4 ± 1.5 mo (P < 0.0001). At the last clinic visit, younger-patient dosing averaged 365 ± 61 mg/d, with older patients averaging 168 ± 18 mg/d (P < 0.0001). Only older patients demonstrated a reduction in visual analog scale scores from start of opioid therapy until discharge from the clinic (6.9 ± 0.3 to 5.6 ± 0.3; P < 0.01). These clinical data suggest that age is an important variable in opioid dose escalation. Although factors other than opioid tolerance can result in dose escalation, it is possible that older patients may have a reduced rate of tolerance development.

This article has been cited by other articles:

				B. B. Yao, G. Hsieh, A. V. Daza, Y. Fan, G. K. Grayson, T. R. Garrison, O. El Kouhen, B. A. Hooker, M. Pai, E. J. Wensink, et al. Characterization of a Cannabinoid CB2 Receptor-Selective Agonist, A-836339 [2,2,3,3-Tetramethyl-cyclopropanecarboxylic Acid [3-(2-Methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], Using in Vitro Pharmacological Assays, in Vivo Pain Models, and Pharmacological Magnetic Resonance Imaging J. Pharmacol. Exp. Ther., January 1, 2009; 328(1): 141 - 151. [Abstract] [Full Text] [PDF]

				N. Katz Methodological issues in clinical trials of opioids for chronic pain Neurology, December 29, 2005; 65(12_suppl_4): S32 - S49. [Abstract] [Full Text] [PDF]

				Y. Wang, J. Mitchell, K. Moriyama, K.-j. Kim, M. Sharma, G.-x. Xie, and P. P. Palmer Age-Dependent Morphine Tolerance Development in the Rat Anesth. Analg., June 1, 2005; 100(6): 1733 - 1739. [Abstract] [Full Text] [PDF]